登录 | 注册    微信公众号  
搜索
>产品&服务 > 脑与神经蛋白产品

脑与神经蛋白

背景
据世界卫生组织的统计,各种退行性、功能性和精神性的脑相关疾病,已为社会造成巨大负担,在所有疾病中占比超过心血管疾病与癌症。以阿尔茨海默病为例,根据World Alzheimer Report的统计数据,早在2015 年全球阿尔茨海默患者人数就有4680 万,全球新增患者 990 万人,这意味着平均每 3 秒钟就有一例新增病例,预计 2030 年增长至7470 万,到 2050 年时,这个数字将会达到 1.3 亿。
重大脑疾病的诊断和干预,是未来脑科学一项非常重要的研究内容,对改善现代社会的健康、推进传统药物工业、新型生物工程企业和发展科学都具有重大意义。
ACRO作为专注于医药研发领域的蛋白供应商,拥有专业的蛋白研发平台、蛋白标记平台、稳定株开发平台和流式细胞分析平台,Aneuro是ACRO聚焦脑科学研究的产品线,为脑科学研究领域提供优质的重要蛋白产品,分享脑科学研究新思路,助力脑科学研究。
治疗研究相关产品
阿尔茨海默病
(Alzheimer′s disease, AD)
阿尔茨海默病(Alzheimer′s disease, AD)是中枢神经退行性病变,表现为认知功能障碍和行为损害,无法治愈,综合治疗可缓解病情、延缓发展。目前有多种学说试图解释这一病变,包括β-淀粉样蛋白瀑布学说、Tau蛋白学说、神经血管假说等。
PP蛋白水解过程的示意图
https://www.sciencedirect.com/science/article/pii/S1552526016000790
APP蛋白水解过程的示意图
代表产品APP/A betaAPOEACHEBACE1BCHE
GSK-3betaTauTREM2
帕金森病
(Parkinson disease,PD)
帕金森病(Parkinson disease, PD)是一种常见于中老年的神经系统变性疾病,主要表现为患者动作缓慢,手脚或身体的其它部分的震颤,身体失去了柔软性,变得僵硬。PD患者黑质中的色素细胞减少,多巴胺能神经元丢失,神经胶质增多,出现路易小体,导致纹状体内抑制性递质多巴胺和兴奋性递质乙酰胆碱相对失衡。
影响PD发病的多种途径
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6905381/
影响PD发病的多种途径
代表产品Alpha-SynucleinDDCMAOAMAOBLRRK2
亨廷顿病
(Huntington disease, HD)
亨廷顿病(Huntington disease, HD),又称为亨廷顿舞蹈症,是一种十分罕见的常染色体显性遗传性的神经系统退行性疾病。患者主要出现不由自主的舞蹈样动作,并可能出现精神行为和认知功能的异常。该病是遗传病,由4号染色体上HTT基因中的CAG片段异常重复引起。
亨廷顿基因(HTT)的毒性机制
https://pubmed.ncbi.nlm.nih.gov/31940909/
亨廷顿基因(HTT)的毒性机制
代表产品HTT
肌萎缩侧索硬化症
(Amyotrophic lateral sclerosis, ALS)
肌萎缩侧索硬化症(Amyotrophic lateral sclerosis, ALS)是一种致命的神经退行性疾病,由大脑和脊髓运动神经元的缺失引起。该病导致四肢、躯干、胸部、腹部肌肉逐渐无力并萎缩,从而影响运动、交流、吞咽和呼吸功能,最终致死。SOD1被发现与家族性肌萎缩侧索硬化症密切相关,是该疾病的重要致病基因。
ALS的病理和疾病机制
https://pubmed.ncbi.nlm.nih.gov/28468939/
ALS的病理和疾病机制
代表产品SOD1TDP-43
多发性硬化
(Multiple sclerosis, MS)
多发性硬化(Multiple sclerosis, MS)是一种以中枢神经系统炎性脱髓鞘病变为主要特点的免疫介导性疾病。多项研究数据表明,B细胞及其产生的自身抗体在MS的发病过程中起到重要的作用。以罗氏、诺华为代表的药企已开发多款B细胞特异性表达的CD20抗体药治疗多发性硬化。
免疫细胞在MS发病机制中的作用
https://pubmed.ncbi.nlm.nih.gov/24740824/
免疫细胞在MS发病机制中的作用
代表产品CD19CD20CD52IFNAR1TGA4
脑肿瘤
(Brain Tumors)
脑肿瘤是发生于颅内的一大类神经系统肿瘤,可分为不同的肿瘤类型,常见有胶质瘤、脑膜瘤、髓母细胞瘤、神经胶质瘤等。
脑肿瘤的治疗将取决于许多因素,包括肿瘤的类型、大小和位置,以及症状、一般健康状况等。靶向药物治疗是脑肿瘤的主要治疗方法之一。
不同类型的脑肿瘤
https://brainmadesimple.com/brain-tumor-cancer/
不同类型的脑肿瘤
代表产品CD117CSFEGFREphA2PDGFVEGFTOP

如有需求或更多开发建议,欢迎与我们联系 留言咨询

诊断研究相关产品
分子 货号 种属 产品描述
APP/A beta APP-H51H8 Human Human APP / Abeta38 Protein, His Tag
APP-H51H7 Human Human APP / Abeta40 Protein, His Tag
APP-H51H6 Human Human APP / Abeta42 Protein, His Tag
Alpha-synuclein ALN-H52H8 Human Human Alpha-Synuclein Protein, His Tag
ALN-H82H8 Human Biotinylated Human Alpha-Synuclein Protein, His,Avitag™
GFAP GFP-H5143 Human Human GFAP Protein, His Tag
GFP-M5148 Mouse Mouse GFAP Protein, His Tag
Neuron Specific Enolase(NSE) NSE-H5144 Human Human NSE Protein, His Tag
Neurofilament Light (NfL) NFL-H5143 Human Human NFL Protein, His Tag
Neurofilament Heavy (NfH) NFH-H5544 Human Human NFH Protein, His Tag
S100B S1B-H5143 Human Human S100B Protein, His Tag
Tau TAU-H51H3 Human Human Tau-441 / 2N4R Protein, His Tag
TAU-H51H5 Human Human Tau-441 / 2N4R (273-380) Protein, His Tag (MALS verified)
TAU-H51H4 Human Human Tau-441 / 2N4R (241-380) Protein, His Tag (MALS verified)
验证数据
高纯度经SDS-PAGE及SEC-MALS验证
TAU-H51H5 (SDS-PAGE&MALS)

The purity of Human Tau-441 (273-380), His Tag (Cat. No. TAU-H51H5) is greater than 95% verified by SDS-PAGE, and more than 90% verified by SEC-MALS.

申请Report

BA1-H5220 (SDS-PAGE&MALS)

The purity of Human BACE-1, His Tag (Cat. No. BA1-H5220) is greater than 95% verified by SDS-PAGE,and more than 95% verified by SEC-MALS.

申请Report

高生物活性经ELISA验证
TREM2-ELISA

Immobilized Human TREM2, His, Tag (Cat. No. TR2-H52H5) at 1 μg/mL (100 μL/well) can bind Anti-TREM2 Antibody, Human IgG1 with a linear range of 0.3-2 ng/mL (QC tested).

申请 Protocol

TREM2-ELISA

Immobilized Human TREM2, Fc Tag (Cat. No. TR2-H5254) at 1 μg/mL (100 μL/well) can bind Anti-TREM2 Antibody, Human IgG1 with a linear range of 1-20 ng/mL (QC tested).

申请 Protocol

CD0-H82E5 (ELISA)

Immobilized Rituximab at 2 μg/mL (100 μL/well) can bind Biotinylated Human CD20 Full Length, His,Avitag (HEK293) (Cat. No. CD0-H82E5) with a linear range of 4-63 ng/mL (in presence of DDM and CHS) (QC tested).

申请 Protocol

IT7-H52W4 (ELISA)

Immobilized anti-alpha4 unit,Human IgG4, kappa LC at 1 μg/mL (100 μL/well) can bind Human ITGA4&ITGB7 Heterodimer Protein, His Tag&Tag Free (Cat. No. IT7-H52W4) with a linear range of 8-31 ng/mL (QC tested).

申请 Protocol

亲和力经SPR验证
TREM2-SPR

Anti-TREM2 antibody captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human TREM2, His Tag (Cat. No. TR2-H52H5) with an affinity constant of 95.9 nM as determined in a SPR assay (Biacore 8K)

申请 Protocol

CD0-H82E5(SPR)

Biotinylated Human CD20, His,Avitag (HEK293) (Cat. No. CD0-H82E5) captured on Biotin CAP-Series S Sensor Chip can bind Rituximab with an affinity constant of 1.73 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore T200) (Routinely tested).

申请 Protocol

亲和力经BLI验证
TREM2-BLI

Loaded Human TREM2, Fc Tag (Cat. No. TR2-H5254) on Protein A Biosensor, can bind Human Apolipoprotein E, His Tag (Cat. No. APE-H5246) with an affinity constant of 106 nM as determined in BLI assay (ForteBio Octet Red96e).

申请 Protocol

TREM2-BLI

Loaded Human TREM2, Fc Tag (Cat. No. TR2-H5254) on Protein A Biosensor, can bind Human Apolipoprotein E (R154S,R176C), His Tag (Cat. No. APE-H5256) with an affinity constant of 17.2 nM as determined in BLI assay (ForteBio Octet Red96e).

申请 Protocol

CD0-H82E5(BLI)

Loaded Biotinylated Human CD20 Full Length, His,Avitag (HEK293) (Cat. No. CD0-H82E5) on SA Biosensor, can bind Rituximab with an affinity constant of 0.247 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

申请 Protocol

IF1-H5225 (BLI)

Loaded Human IFNAR1, His Tag (Cat. No. IF1-H5225) on NTA Biosensor, can bind Human IFN-alpha 2b (K46R), Fc Tag (Cat. No. IFB-H5253) with an affinity constant of 0.689 μM as determined in BLI assay (ForteBio Octet Red96e) (QC tested).

申请 Protocol

相关阅读

> 【前沿进展】【聚焦】阿尔兹海默病发病机制的三大主流学说

> 【前沿进展】【聚焦】第二常见的神经退行性疾病:帕金森病

> 【前沿进展】【聚焦】“渐冻症”:肌萎缩侧索硬化症

> 【前沿进展】【聚焦】多发性硬化症

> 【靶点聚焦】【聚焦】脑肿瘤的经典、潜力、创新三大治疗策略

相关参考文献
  • 1. Myasnikov, A., H. Zhu, P. Hixson, B. Xie, K. Yu, A. Pitre, J. Peng and J. Sun (2021). "Structural analysis of the full-length human LRRK2." Cell 184(13): 3519-3527 e3510.
  • 2. Knopman, D. S., H. Amieva, R. C. Petersen, G. Chetelat, D. M. Holtzman, B. T. Hyman, R. A. Nixon and D. T. Jones (2021). "Alzheimer disease." Nat Rev Dis Primers 7(1): 33.
  • 3. Bloem, B. R., M. S. Okun and C. Klein (2021). "Parkinson's disease." Lancet 397(10291): 2284-2303.
  • 4. Tabrizi, S. J., M. D. Flower, C. A. Ross and E. J. Wild (2020). "Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities." Nat Rev Neurol 16(10): 529-546.
  • 5. Reich, D. S., C. F. Lucchinetti and P. A. Calabresi (2018). "Multiple Sclerosis." N Engl J Med 378(2): 169-180.
  • 6. Pan, X., Z. Li, Q. Zhou, H. Shen, K. Wu, X. Huang, J. Chen, J. Zhang, X. Zhu, J. Lei, W. Xiong, H. Gong, B. Xiao and N. Yan (2018). "Structure of the human voltage-gated sodium channel Nav1.4 in complex with beta1." Science 362(6412): eaau2486.
  • 7. Lapointe, S., A. Perry and N. A. Butowski (2018). "Primary brain tumours in adults." Lancet 392(10145): 432-446.
  • 8. Brown, R. H. and A. Al-Chalabi (2017). "Amyotrophic Lateral Sclerosis." N Engl J Med 377(2): 162-172.

文献下载

消息提示

请输入您的联系方式,再点击提交!

确定